Eosinophilic gastrointestinal disorders (EGID) are rare conditions characterized by eosinophilic infiltration of the bowel wall and gastrointestinal symptoms. These disorders can present with various manifestations, depending on the specific site of the affected gastrointestinal tract and specific layer of the affected gastrointestinal wall. The pathogenesis and etiology of EGID remain unclear. The present case report describes a 76-year-old woman who presented with chronic diarrhea and lower abdominal pain. The patient was successfully treated with corticosteroid and restriction of some food allergens. One needs to consider these rare disorders during the differential diagnosis of unexplained gastrointestinal symptoms, especially when they are associated with peripheral eosinophilia.
erefore, family medicine doctors as primary physicians should be aware of systematic approaches and various experiences pertaining to this condition.
Eosinophilic gastrointestinal disorders (EGID) are one of rare causes of chronic diarrhea. The disorders are characterized by inflammation rich in eosinophilic infiltration in the gastrointestinal (GI) tract without evidence of known causes for eosinophilia such as parasitic infection, drug reaction, or malignancy. [3] [4] [5] It was originally described by Kaijser 6) in 1937;
since then, hundreds of cases have been described from all over the world including North America, Europe, Australia, and Asia. 7) Diverse cases of EGID have also been reported in Korea. 8, 9) EGID can involve one or multiple segments of the GI tract from the esophagus to the rectum (mainly in the antrum of the stomach and small intestine), 10) and can also occupy various sites through the depth of the wall. Such inconsistency from case to case promotes unpredictable symptoms from pain to dysmotility, bleeding, obstruction, or ascites.
11)
About half of EGID cases present with allergic features, and some may be related to food allergy. 12) However, there are few reports of EGID associated with adults, especially with the
INTRODUCTION
Chronic diarrhea is a common condition in primary care.
1)
The various definitions of chronic diarrhea commonly include the presence of loose stools that last for at least 4 weeks. By one estimate, it occurs in up to 3-5% of population in United States.
2)
Pathophysiologically, the major causes of chronic diarrhea include osmotic, secretory, in ammatory, and functional factors. Chronic diarrhea is a treatment challenge, even for experienced clinicians. Presently, this concept is most commonly used in de ning EGID.
In published reports, stomach (26-81%) and small intestine (28-100%) are the predominantly a ected sites but esophagus, large intestine, and rectum may be a ected as well. 7) EGID consist of heterogeneous subtypes including eosino philic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis. Although some researchers regard eosinophilic gastroenteritis as a synonym for EGID, others have used this term to refer to eosinophilic in ammation exclusively to the stomach and small intestine. To avoid redundancy in this issue, this article restricted eosinophilic gastroenteritis as the la er. 16) EGID are exceedingly rare, lacking epidemiological data to estimate their true frequency. EGID a ect all races and ages, from infancy through adulthood, peaking during the second and sixth decades of life. 5) Contrary to other subtypes, eosinophilic colitis mucosa from the cecum to the sigmoid colon ( Figure 1 ).
Multiple random biopsies were taken. The pathologic findings revealed di use in ltration of eosinophils and lymphocytes in the lamina propria, especially on the descending colon ( Figure 2 ).
Abdominal computed tomography was unremarkable except for a simple renal cyst.
e patient was admi ed to our hospital for further evalua- 19) Some studies point to a T cell-mediated process, but the exact immunologic mechanisms for this have not been identified. 3, 13) Similarly, the present case was normal in total and antigen-speci c in ltration must be excluded before the diagnosis is con rmed.
As a result, it is all very common for patients with these disorders to be symptomatic for extended periods before an accurate diagnosis is made.
22)
Pathologic evaluation to prove eosinophilic infiltration is essential to confirm the diagnosis. Eosinophils are normally present in the lamina propria of the gut mucosa, except the esophagus. 4) ere is generally no agreement on what constitutes a pathological number of eosinophils. In most of the publications involving large case series, a cut-o of ≥20 eosinophils per high power field has been used to define EGID histologically. 14, 15, 23) In the present case, the tissue eosinophil numbers were also consistent with this definition. The diagnosis of the muscular form of EGID may require laparoscopic full-thickness biopsies.
In eosinophilic colitis, there may be diffuse or focal aggregates in the lamina propria, crypt epithelium, and muscular mucosa preserving the underlying mucosal architecture.
The differential diagnosis of EGID includes secondary eosinophil-associated GI disorders, such as hypereosinophilic syndromes, parasitic infections, inflammatory bowel diseases, celiac disease, food allergies, neoplasia, connective tissue disorders (e.g., scleroderma and dermatomyositis) collagen vascular disorders (e.g., polyarteritis nodosa and Churg-Strauss syndrome), and use of medications. 4, 5, 7) Evaluation for idiopathic hypereosinophilic syndrome (HES)
in patients with apparent EGID is important. is strategy, which has been established with great success in children, is also used in adults, and has a very high response rate (close to 100% within 3 weeks), although it is di cult for most patients to maintain such a strict diet. 12) If no food sensitization is discovered, or if a targeted elimination diet is not feasible or has failed to alleviate symptoms, systemic (for acute exacerbations) or topical glucocorticoids can be considered for therapy. 5, 7) The recommended dose is prednisolone 20-40 mg/day for 1-2 weeks. The dose is then tapered off over several weeks. 4) Up to 90% of cases will respond dramatically within 2 weeks of treatment. 22) However, a maintenance does of prednisolone (10 mg/day) and cessation of corticosteroids has resulted in recurrence of symptoms in 15%
and 55% of patients, respectively. 25) In eosinophilic esophagitis, swallowing topical fluticasone did not produce significant diffe rences in efficacy or relapse, compared to oral steroid, although fewer adverse events were noted for fluticasone. 26) Less well-documented treatments such as mast cell stabilizer (cromoglycate), leukotriene antagonist (montelukast), and antihistamines (ketotifen) have been reported in small, uncontrolled trials. 25) Experimental treatment with anti-IL-5 antibody (mepolizumab) seems, in general, to be the most promising, and is a putative treatment for severe or therapy-resistant EGID. 27) In severe cases, refractory or dependent on systemic glucocorticoid therapy, intravenous alimentation or immunosuppressive antimetabolite therapy (azathioprine or 6-mercaptopurine) are alternatives.
3)
